Ultragenyx Pharmaceutical Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Hi, good afternoon. This is Liisa Bayko, biotech analyst at Evercore ISI. Very pleased to be joined by Ultragenyx, a great company, work on rare diseases and taking all sorts of different approaches. I feel like you have almost every treatment modality under the sun from gene editing to mRNA to -- well, gene therapy, to mRNA, to small molecules, et cetera, antibodies. Emil Kakkis started the company quite a while ago and has done a great job leading the charge.
Questions & Answers
So I think we'll just jump right in because we only have 20 minutes, and I hate to hammer on Angelman because I feel like that's all you get asked about. So let's just ask a couple of questions there and get that off the way and then move on to some other stuff. I guess we're looking for data sometime soon in December. What would you be looking for in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
